1. Clinical & Scientific Overview
Bortezomib (TIP-MED-000574, Reference Code [ONC-25]) is classified under
Oncology & Antineoplastic Medicines as a Targeted Therapy (Proteasome Inhibitor) • Reversible Dipeptidyl Boronic Acid 26S Proteasome Inhibitor.
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Specialist Oncology Supervision).
Velcade (Janssen), Bortecad (Cadila Pharmaceuticals), Myelison (Natco Pharma)
Lyophilised Powder for Subcutaneous or IV Injection: 2 mg vial, 3.5 mg vial
Oncology Specialisation & Cytotoxic Safety Protocol
Targeted Therapy (Proteasome Inhibitor)
Antineoplastic Targeted Agent
Standard Regimen & Cycle Context: 1.3 mg/m2 SUBCUTANEOUSLY (preferred over IV push) on Days 1, 4, 8, and 11 (or weekly on Days 1, 8, 15, 22) of a 21- or 28-day cycle.
Signature Dose-Limiting Toxicities & Organ Monitoring: Dose-limiting Sensory Peripheral Neuropathy (reduced from 53% to 38% by switching from IV to Subcutaneous route and weekly dosing!), Herpes Zoster (Varicella-Zoster Virus) reactivation (requires mandatory Acyclovir/Valacyclovir prophylaxis), cyclical thrombocytopenia (platelets dip and recover between doses), and postural hypotension; NEVER administer intrathecally (fatal).
Extravasation, Premedication & Safe Cytotoxic Handling: Administer via the SUBCUTANEOUS route (reconstituted to 2.5 mg/mL in 0.9% NaCl vs 1 mg/mL for IV — verify concentration closely to prevent 2.5x dosing error!), prescribe mandatory oral Acyclovir 400 mg BD for shingles prophylaxis, and tell patients to avoid high-dose green tea extract (EGCG directly binds the boronic acid moiety of bortezomib and neutralises its anticancer activity!).
3. Mechanism of Action & Pharmacodynamics
Boronic acid moiety reversibly binds the chymotrypsin-like beta-5 catalytic site of the 26S proteasome, blocking degradation of I-kappa-B (which traps NF-kappa-B in the cytoplasm) and triggering fatal unfolded protein stress (ER stress) in immunoglobulin-hypersecreting myeloma plasma cells.
4. Therapeutic Indications & Evidence-Supported Uses
- Multiple Myeloma (VRd, CyBorD, and Daratumumab-based regimens)
- Mantle Cell Lymphoma
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Oncology Regimen Context (Specialist Reference Only): 1.3 mg/m2 SUBCUTANEOUSLY (preferred over IV push) on Days 1, 4, 8, and 11 (or weekly on Days 1, 8, 15, 22) of a 21- or 28-day cycle.
Administration & Meal Timing: 1.3 mg/m2 SUBCUTANEOUSLY (preferred over IV push) on Days 1, 4, 8, and 11 (or weekly on Days 1, 8, 15, 22) of a 21- or 28-day cycle.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Specialist oncology pharmacokinetic profile; dosing depends on Body Surface Area (BSA in m2), Calvert GFR formula, or flat targeted dosing with strict organ-function adjustments.
Hepatic enzymatic activation/inactivation or proteolytic degradation (for monoclonal antibodies); see specific polymorphism and interaction notes.
Verify serum creatinine and eGFR before every cycle; see drug-specific renal dosing and uroprotection rules.
Check total bilirubin, AST, and ALT prior to each cycle; taxanes, anthracyclines, and TKIs require strict hepatic dose modification.
7. Contraindications, Precautions & High-Risk Warnings
- Severe hypersensitivity to Bortezomib or formulation vehicle
- Pregnancy and lactation (potent teratogen/embryotoxic class warning unless explicitly evaluated by oncology specialist)
- Severe unrecovered bone marrow aplasia or decompensated organ failure per protocol thresholds
Key Clinical Precautions: Dose-limiting Sensory Peripheral Neuropathy (reduced from 53% to 38% by switching from IV to Subcutaneous route and weekly dosing!), Herpes Zoster (Varicella-Zoster Virus) reactivation (requires mandatory Acyclovir/Valacyclovir prophylaxis), cyclical thrombocytopenia (platelets dip and recover between doses), and postural hypotension; NEVER administer intrathecally (fatal).
8. Adverse Effects Profile
- Dose-limiting Sensory Peripheral Neuropathy (reduced from 53% to 38% by switching from IV to Subcutaneous route and weekly dosing!), Herpes Zoster (Varicella-Zoster Virus) reactivation (requires mandatory Acyclovir/Valacyclovir prophylaxis), cyclical thrombocytopenia (platelets dip and recover between doses), and postural hypotension; NEVER administer intrathecally (fatal).
- Dose-limiting Sensory Peripheral Neuropathy (reduced from 53% to 38% by switching from IV to Subcutaneous route and weekly dosing!), Herpes Zoster (Varicella-Zoster Virus) reactivation (requires mandatory Acyclovir/Valacyclovir prophylaxis), cyclical thrombocytopenia (platelets dip and recover between doses), and postural hypotension; NEVER administer intrathecally (fatal).
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Dose-limiting Sensory Peripheral Neuropathy (reduced from 53% to 38% by switching from IV to Subcutaneous route and weekly dosing!), Herpes Zoster (Varicella-Zoster Virus) reactivation (requires mandatory Acyclovir/Valacyclovir prophylaxis), cyclical thrombocytopenia (platelets dip and recover between doses), and postural hypotension; NEVER administer intrathecally (fatal).
- Avoid live-attenuated vaccines during immunosuppressive chemotherapy; verify CYP3A4, UGT1A1, DPD, and QTc interactions before each cycle.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Administer via the SUBCUTANEOUS route (reconstituted to 2.5 mg/mL in 0.9% NaCl vs 1 mg/mL for IV — verify concentration closely to prevent 2.5x dosing error!), prescribe mandatory oral Acyclovir 400 mg BD for shingles prophylaxis, and tell patients to avoid high-dose green tea extract (EGCG directly binds the boronic acid moiety of bortezomib and neutralises its anticancer activity!).
Pharmacist Patient Counselling Points:
- Administer via the SUBCUTANEOUS route (reconstituted to 2.5 mg/mL in 0.9% NaCl vs 1 mg/mL for IV — verify concentration closely to prevent 2.5x dosing error!), prescribe mandatory oral Acyclovir 400 mg BD for shingles prophylaxis, and tell patients to avoid high-dose green tea extract (EGCG directly binds the boronic acid moiety of bortezomib and neutralises its anticancer activity!).
- Report fever >=38.0°C (100.4°F) immediately (medical emergency: possible febrile neutropenia).
- Follow strict reproductive contraception and safe cytotoxic oral handling instructions.
Storage, Stability & Dispensing Safeguards: Administer via the SUBCUTANEOUS route (reconstituted to 2.5 mg/mL in 0.9% NaCl vs 1 mg/mL for IV — verify concentration closely to prevent 2.5x dosing error!), prescribe mandatory oral Acyclovir 400 mg BD for shingles prophylaxis, and tell patients to avoid high-dose green tea extract (EGCG directly binds the boronic acid moiety of bortezomib and neutralises its anticancer activity!).
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: National Cancer Grid (NCG) India Consensus Guidelines; NLEM 2022 Antineoplastic Section; Indian Pharmacopoeia (IP) & CDSCO Approved Oncology Prescribing Information.
Official Verification Portals: National Cancer Grid (NCG) India — Evidence-Based Oncology Guidelines • CDSCO — Central Drugs Standard Control Organization Approved Drug Data • Indian Pharmacopoeia Commission (IPC)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.